Vir Biotechnology, Inc. (VIR - Free Report) was a big mover last session, as the company saw its shares rise 6% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $28.28 to $39.11 in the past one-month time frame.
This move came after the company announced that its joint venture with GlaxoSmithKline is entering the Phase 3 trials of its latest COVID-19 antibody treatment.
The company has seen one positive estimate revision in the past few months, while its Zacks Consensus Estimate for the current quarter has also moved higher over the past few months, suggesting that more solid trading could be ahead for Vir Biotechnology. So make sure to keep an eye on this stock going forward to see if this recent jump can turn into more strength down the road.
Vir Biotechnology, Inc. Price
Vir Biotechnology currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.
A better-ranked stock in the Medical - Biomedical and Genetics industry is Emergent BioSolutions Inc (EBS - Free Report) , which currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Biggest Tech Breakthrough in a Generation
Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity.
A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 8 stocks to watch. The report is only available for a limited time.
See 8 breakthrough stocks now>>